Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Clear filter
665 clinical trials found
Clinical trials

Portico NG

Portico NG - Evaluation of the Navitor Transcatheter Aortic Valve in High and Extreme Risk Patients with Symptomatic Severe Aortic Stenosis

The primary objective of this clinical study is to evaluate the acute safety and effectiveness of the Navitor Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days. The results from this study will be descriptively compared to the data from the first-generation Portico Transcatheter Aortic Heart Valve and commercially available TAVI devices studied in the same patient population (e.g. high and extreme surgical risk).

No longer recruiting

PRAX-628-212

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures (NCT06908356)

The main purpose of this study is to see how well PRAX-628 works in treating focal onset seizures (the type of seizure that starts when only one area of the brain starts firing uncontrolled electrical signals) and primary generalised tonic-clonic seizures (the type of seizure that occurs when uncontrolled electrical activity affects the entire brain from the start). Additional purposes of this study are to see how safe PRAX-628 is and how the body processes (pharmacokinetics, PK) it. In this study, all participants will receive PRAX-628 30 mg (3 x 10 mg capsules) once daily (QD) for 8 weeks.
Currently recruiting

PREVENT-NEURO

Prophylaxis against early ventilator-associated infections to reduce mortality in mechanically ventilated ICU patients with acute brain injuries (NCT06819592)

The PREVENT-NEURO study will test the hypothesis that among adults with acute brain injuries receiving invasive mechanical ventilation in the ICU (participants), one dose of 2g of intravenous ceftriaxone administered as soon as practical after endotracheal intubation (intervention), compared to a matched placebo (comparator), reduces 90-day mortality (primary outcome).
Coming soon

PRIME-OOHCA

PRotecting cerebral injury and IMproving outcomEs with SGLT2 inhibitors in comatose Out-Of-Hospital Cardiac Arrest survivors – a Pilot Study (ACTRN12624001183572)

A double blinded randomised controlled pilot study comparing the outcomes of dapagliflozin vs placebo in patients with comatose cardiac arrest, with respect to hypoxic brain and ischaemia reperfusion injury
Currently recruiting

PROBE-DFU Trial

Pilot randomised controlled trial of probe to bone diabetic foot ulcer therapy (ACTRN12624000266561)

Probe-to-bone (PTB) test is a bedside test used to assess for bone infection in patients with diabetic foot ulcers, where a blunt metal probe is used to test for presence of bone within the ulcer bed. This study aims to evaluate the safety and feasibility of treating patients with diabetic foot ulcers and positive PTB test with shorter courses of antibiotic therapy in a low-risk setting.
Currently recruiting

PROMPT

Ultra-hyPofractionated stereotactic Radiation therapy for de nOvo Metastatic ProsTate cancer (ACTRN12626000470392)

A prospective, multi-centre, single-arm non-randomised phase 2 clinical trial. This study will aim to deliver SABR to the prostate 35 Gy in 5 fractions, one fraction per week, in individuals with de novo metastatic prostate cancer.
Currently recruiting

PROMPT O2

Perioperative Medicine Platform Trial (NCT07186634)

Giving a lot of oxygen may decrease the risk of infections after surgery. On the other hand, it is also possible that giving a conservative amount of oxygen (instead of a large amount) might protect organ functions and improve other aspects of recovery after surgery. We are comparing three (3) different ways of giving oxygen. You have an equal chance of receiving one of the following three treatments during and after surgery: Liberal oxygen - at least 80% oxygen; Conservative oxygen - the smallest amount of oxygen needed to safely achieve normal oxygen levels in the blood (but more than the oxygen in room air); Standard oxygen - oxygen in a middle range between the liberal and conservative treatments.
Currently recruiting

PSO-Withdraw

A Proof-of-concept Single-arm clinical trial Of semaglutide after withdrawal of biologic therapy for chronic plaque psoriasis in people with overweight/obesity [PSO-withdraw] (Trial Not Registered)

This study is seeking adults who are currently on a biologic therapy for their chronic plaque psoriasis and are classified as overweight/obese. The study aims to investigate whether starting semaglutides after stopping biologic therapy can maintain disease remission in this patient population. Eligible participants will be followed over one year and need to attend the Alfred Hospital for at least 10 visits over this time. Blood samples, quality of life questionnaires and assessments will be undertaken at each of these visits.
Coming soon